Data as of 2026-10-12.
Lymphomas divide first into Hodgkin and non-Hodgkin lymphoma (NHL). NHL is itself an umbrella for many B- and T-cell entities; the highest-volume B-cell subtypes, DLBCL, follicular, mantle cell, and CLL/SLL, each carry their own pipeline of targeted agents, bispecific antibodies, and cell therapies. Tracking lymphoma well means watching both the broad NHL category and the individual subtype races, since a single new bispecific or CAR-T program often spans several of them.
Non-Hodgkin lymphoma is an umbrella covering the B-cell subtypes listed below, so the rows overlap and do not sum to the total above. CLL/SLL is biologically a small-cell B-cell lymphoma and is included here as well as on the blood-cancer hub.
Major categories
| Subtype | Active | Recruiting | Phase 3 |
|---|---|---|---|
| Non-Hodgkin Lymphoma | 1290 | 714 | 95 |
| Hodgkin Lymphoma | 228 | 122 | 12 |
B-cell non-Hodgkin subtypes
| Subtype | Active | Recruiting | Phase 3 |
|---|---|---|---|
| Chronic Lymphocytic Leukemia / SLL | 391 | 187 | 44 |
| Diffuse Large B-Cell Lymphoma (DLBCL) | 564 | 305 | 51 |
| Follicular Lymphoma | 269 | 139 | 30 |
| Mantle Cell Lymphoma | 212 | 107 | 11 |
Track every new lymphoma trial automatically
ClinicalTrials.gov updates daily. Our pipeline monitors it for you and delivers a clean digest every morning.
Get the free digest, no credit cardLargest industry-sponsored lymphoma trial portfolios by active study count:
| Industry sponsor | Active trials |
|---|---|
| AstraZeneca | 26 |
| Roche / Genentech | 21 |
| Merck (MSD) | 17 |
| Bristol-Myers Squibb | 16 |
| AbbVie | 14 |
Our pipeline pulls from ClinicalTrials.gov every day. For a lymphoma watchlist or saved search, your digest covers:
- New study registrations and status changes (for example opened to recruiting, completed)
- Protocol changes: enrollment, endpoints, phase, and completion-date movements
- New sponsor entrants into a subtype
- Phase filters (Phase 1 for novel mechanisms, Phase 3 for registration programs)
- Sponsor-type filters (large pharma vs. emerging biotech vs. academic)
Ready to automate your lymphoma trial monitoring?
Free plan, no credit card required. Set up your profile in 2 minutes.
Start freeFrequently asked questions
DataLookout checks ClinicalTrials.gov every day and records what changed on each trial: status, enrollment, phase, primary endpoint, completion dates, sites, sponsor, and the stated reason a trial stopped. Add a sponsor or a disease to your watchlist, or save any search, and the changes arrive in a daily or weekly email digest.
Free, $0 forever: 1 sponsor + 1 disease watchlist, 1 saved search in your email digest, track up to 5 individual trials, daily change detection, Trials at Risk (top 2 trials), the weekly report (top 3 trials). No credit card.
Pro, $49/month or $490/year: 10 sponsor + 10 disease watchlists, 10 saved searches in your email digest, track up to 25 individual trials, full Trials at Risk list, Completions calendar, the full weekly report, landscape reports, CSV export.
Data as of 2026-10-12, from ClinicalTrials.gov. View the full pipeline on the dashboard.